Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men-Reference-Cited by-同舟云学术

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men

Published:2022-03-15 Issue:3 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Han Kelong¹^ORCID,Wannamaker Paul²,Lu Hongzhou³,Zhu Biao⁴,Wang Meixia⁵,Paff Melanie¹,Spreen William R.²,Ford Susan L.⁶

Affiliation:

1. GlaxoSmithKline, Collegeville, Pennsylvania, USA

2. ViiV Healthcare, Research Triangle Park, North Carolina, USA

3. Shanghai Public Health Clinical Center, Fudan University, Shanghai, China

4. The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

5. State Drug Clinical Trial Institution, Beijing Youan Hospital, Capital Medical University, Beijing, China

6. GlaxoSmithKline, Research Triangle Park, North Carolina, USA

Abstract

Long-acting (LA) cabotegravir demonstrated superior efficacy versus daily oral standard-of-care for HIV-1 preexposure prophylaxis. This phase 1 study assessed safety, tolerability, pharmacokinetics, and acceptability of cabotegravir in 47 HIV-negative adult Chinese men at low risk of acquiring HIV-1.

Funder

ViiV Healthcare

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02057-21

Reference37 articles.

1. UNAIDS. 2021. Fact sheet – World AIDS Day 2021. Global HIV statistics. UNAIDS Geneva Switzerland. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf.

2. Preexposure Prophylaxis for HIV Prevention

3. Gilead Sciences Inc. 2020. Truvada: prescribing information. Gilead Sciences Inc South San Francisco CA.

4. Gilead Sciences Inc. 2021. Descovy: prescribing information. Gilead Sciences Inc South San Francisco CA.

5. National Institutes of Health. 2021. The basics of HIV prevention. National Institutes of Health Bethesda MD. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/basics-hiv-prevention.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implications of Accumulation of Clonally Expanded and Senescent CD4 ⁺ GNLY ⁺ T Cells in Immunological Non-responders of HIV-1 infection;Emerging Microbes & Infections;2024-09-06

2. Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP;Antimicrobial Agents and Chemotherapy;2024-05-06

3. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants;Antimicrobial Agents and Chemotherapy;2024-01-10

4. Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96;HIV Medicine;2023-12-26

5. Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans;Pharmaceutics;2023-11-30